Key result
Subcutaneous IGF-I suppresses GH secretion ~50% and reduces insulin requirements in diabetic adolescents.
Why the study?
Does subcutaneous IGF-I infusion alter GH-IGF dynamics and reduce insulin requirements in adolescents with insulin-dependent diabetes mellitus?
Does subcutaneous IGF-I infusion alter GH-IGF dynamics and reduce insulin requirements in adolescents with insulin-dependent diabetes mellitus?
Subcutaneous IGF-I infusion in diabetic adolescents reduces insulin requirements and suppresses GH secretion without causing hypoglycemia.
No takes yet. Share an insight, caveat, or question.
May reduce insulin requirements in diabetic adolescents via GH suppression; leaves open long-term safety and efficacy.
Bach et al. (1994) studied Insulin-dependent diabetes mellitus (n=10). Recombinant human IGF-I vs. Saline was evaluated on IGF system parameters and growth hormone (GH) secretion. Subcutaneous infusion of IGF-I produced a 3-fold increase in serum IGF-I, suppressed GH secretion by about 50%, and substantially reduced insulin requirements in diabetic adolescents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: